GLP-1 Pros and Cons 2026: Benefits, Risks, Cost

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re weighing the pros and cons of GLP-1 medications in 2026, the honest answer isn’t a one-line yes or no. GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide — produce some of the largest average weight-loss numbers ever documented for a non-surgical intervention, and the cardiovascular and metabolic benefits are increasingly well-characterized. They also come with a real side-effect profile, real cost considerations, and a maintenance question that doesn’t go away when you hit goal weight. This article walks the trade-offs the way a clinician would: what GLP-1s actually do, what the data shows about benefits, what the data shows about risks, what they cost, who shouldn’t use them, and where PlexusDx Weight Management Protocols — Semaglutide Injection, Tirzepatide Injection, Microdose GLP-1 Protocol, and the Precision Peptide Genetic Test — fit relative to the broader GLP-1 landscape.

What GLP-1 medications actually do

GLP-1 stands for “glucagon-like peptide-1,” a gut hormone your body releases after meals. The drug class — GLP-1 receptor agonists — mimics that hormone’s signal in a longer-lasting, stronger form. The result is three overlapping effects: appetite suppression and reduced “food noise,” slower gastric emptying so meals feel filling earlier, and improved insulin response after eating. Tirzepatide (Mounjaro, Zepbound) is technically a dual GIP/GLP-1 receptor agonist — it activates a second receptor (GIP) alongside GLP-1, which is one reason its weight-loss numbers run higher than semaglutide’s in head-to-head data. Across the FDA-approved branded products (Wegovy, Ozempic, Saxenda, Rybelsus, Zepbound, Mounjaro, Trulicity, Victoza), the active ingredient and brand are the same molecule under a different label and indication. Compounded semaglutide and tirzepatide — what PlexusDx and other cash-pay platforms dispense — contain the same active ingredients prepared by licensed U.S. compounding pharmacies, but they are not FDA-approved finished drug products.

The pros: what GLP-1s do well

The benefit case for GLP-1 receptor agonists is genuinely strong. Weight loss is the headline pro: in pivotal trials, semaglutide 2.4 mg (Wegovy) produced average total body weight loss in the mid-teens percent range, and tirzepatide 15 mg (Zepbound) produced averages in the low-20s percent range — numbers that historically required bariatric surgery. Appetite and food-noise reduction is the lived-experience pro most patients comment on: the constant mental loop about the next meal quiets down. Cardiometabolic improvement is the under-appreciated pro: GLP-1 use is associated with improvements in A1c, fasting glucose, blood pressure, lipid panel, and, in the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with established cardiovascular disease. Indication breadth keeps growing — Zepbound is now FDA-approved for obstructive sleep apnea in adults with obesity, and additional indications (NASH/MASH, kidney disease, addiction-adjacent endpoints) are under investigation. For a cash-pay patient who wants the most affordable monthly entry point into this benefit profile, the Microdose GLP-1 Protocol at $129/mo flat is the lowest-cost door into the class.

The cons: what GLP-1s do poorly — or carry as risks

The trade-offs are equally real and worth naming clearly. Gastrointestinal side effects are the most common con: nausea, vomiting, diarrhea, constipation, abdominal pain, and bloating affect a large share of patients, particularly during dose increases, with rates for individual symptoms typically running from the teens up to roughly 40 percent depending on dose and drug. Serious but uncommon risks include pancreatitis, gallbladder disease, acute kidney injury (often dehydration-driven secondary to GI symptoms), and a boxed warning for thyroid C-cell tumors that applies to both semaglutide and tirzepatide based on rodent studies — relevance to humans is unknown but the contraindication for personal or family history of medullary thyroid carcinoma or MEN2 is real. Cost is a structural con: branded Wegovy or Zepbound list prices run roughly $1,000–$1,350/month before insurance, and insurance coverage for weight-loss indications is inconsistent. Weight regain after stopping is the maintenance con: in the STEP 1 extension data, participants regained roughly two-thirds of lost weight within a year of stopping semaglutide, which is why most clinicians treat GLP-1 therapy as long-term rather than a finite course. Lean-mass loss is the under-discussed con: roughly a quarter to 40 percent of weight lost on GLP-1s can come from lean mass unless the patient pairs treatment with resistance training and adequate protein.

Pros and cons by formulation: pills, injections, microdose

Not every GLP-1 is the same delivery format, and the pros and cons shift by route. Weekly injections (semaglutide 0.25–2.0 mg or tirzepatide 2.5–15 mg) offer the highest weight-loss efficacy in trial data and a once-weekly schedule, but require refrigeration and a subcutaneous needle. PlexusDx’s Semaglutide Injection at $149/mo and Tirzepatide Injection at $249/mo cover this format for cash-pay patients without insurance coverage. Daily oral GLP-1s (Rybelsus 3–14 mg and the new oral Wegovy 25 mg) eliminate the needle but require strict fasting and post-dose timing — the molecule is degraded by stomach acid, so an empty stomach and a 30-minute wait before food/drink/other meds are non-negotiable. PlexusDx Semaglutide Oral at $249/mo and Tirzepatide Oral at $279/mo offer compounded oral options. Microdose / low-dose GLP-1 protocols use smaller, more frequent dosing across capsule, troche, lozenge, or sublingual delivery — the pro is tolerability and a lower price point ($129/mo flat on the Microdose GLP-1 Protocol); the con is that microdosing typically produces more modest weight-loss numbers than full-dose injectable regimens. Dual-compound stacks like GLP-Squared ($249/mo) combine semaglutide and tirzepatide and are typically reserved for patients who’ve already established tolerance on a single agent.

Who’s a candidate — and who isn’t

FDA labels for the weight-loss indication require a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease). Beyond eligibility, the “good candidate” conversation includes patients who have tried lifestyle intervention without sustained success, who have insurance coverage or accept cash-pay pricing, and who are willing to commit to long-term therapy. The hard contraindications are non-negotiable: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of severe allergic reaction to the drug class, and pregnancy or active attempt to conceive. Caution categories — not absolute stops — include personal history of pancreatitis, severe gastroparesis, active gallbladder disease, eating-disorder history, or planned surgery within a few weeks (GLP-1s slow gastric emptying and the anesthesia team needs to know). For patients who want the dose and titration conversation anchored to their own biology rather than population averages, the Precision Peptide Genetic Test ($298 standalone, or $99 as an add-on after the first month of any protocol) maps GLP1R, GIPR rs1800437, FTO, MC4R, and TCF7L2 variants alongside 34 weight-management insights.

Cost realities and how PlexusDx Weight Management Protocols compare

The cost picture in 2026 has more options than it did two years ago. Branded Wegovy and Zepbound list prices run roughly $1,000–$1,350/month at retail; manufacturer self-pay programs — Lilly Direct for Zepbound and the Wegovy savings program — reduce cash prices to roughly $349–$499/month for select doses. Telehealth platforms that dispense compounded semaglutide or tirzepatide typically run $179–$499/month depending on dose and platform. PlexusDx Weight Management Protocols sit in the cash-pay compounded segment with no membership fee and no insurance dependency: Microdose GLP-1 Protocol at $129/mo flat ($1,548/year), Semaglutide Injection at $149/mo ($2,148–$2,748/year), Semaglutide Oral at $249/mo ($2,508/year), Tirzepatide Injection at $249/mo ($2,748–$3,708/year), Tirzepatide Oral at $279/mo, and GLP-Squared at $249/mo. All protocols are all-inclusive: async provider consultation (or live consultation in the five states that require it), prescription, compounded medication, and shipping in one bill. PlexusDx ships to all 50 states, no insurance, no membership.

Compounded vs FDA-approved — the oversight question

Branded Wegovy, Ozempic, Saxenda, Rybelsus, Zepbound, Mounjaro, Trulicity, and Victoza are FDA-approved finished drug products with full labeling and post-market surveillance attached. Compounded semaglutide and tirzepatide contain the same active ingredients but are regulated under U.S. compounding law rather than as approved finished drugs — the FDA approval and label apply to the molecule’s branded form, not to the compounded preparation. The FDA has warned about counterfeit GLP-1 products outside the licensed-pharmacy channel; selecting a platform that uses licensed U.S. compounding pharmacies and clinician-issued prescriptions is the practical safety floor. PlexusDx uses licensed U.S. compounding pharmacies and routes every protocol through a licensed clinician; the boxed warning for thyroid C-cell tumors and the standard contraindications apply to compounded products the same way they apply to branded ones.

Frequently asked questions

Are GLP-1 medications safe for most adults?

For eligible adults without contraindications, GLP-1 receptor agonists have been studied extensively and are generally considered safe under clinician supervision. Common side effects (nausea, constipation, diarrhea) are typically manageable and improve with slow dose titration. Patients with a personal or family history of medullary thyroid carcinoma, MEN2, severe allergic reaction to the class, or who are pregnant should not use them. Discuss your full medical history with your prescriber.

How long do I need to stay on a GLP-1 to keep the weight off?

Current evidence suggests most patients need long-term therapy — potentially indefinite — to maintain weight loss; STEP 1 extension data showed roughly two-thirds of lost weight returns within a year of stopping semaglutide. Some patients can step down to a lower maintenance dose; others stay at full dose. PlexusDx protocols are designed for sustained use and bill monthly with no annual contract.

What happens if I stop my GLP-1 abruptly?

Appetite and food-noise return toward baseline, gastric emptying normalizes, and most patients regain a substantial share of lost weight within 12 months. Cardiometabolic improvements (blood pressure, A1c, lipids) may partially reverse. If you’re considering stopping, work with your prescriber on a tapered exit and a plan for restart if weight rebounds.

Do GLP-1 medications cause muscle loss?

Roughly a quarter to 40 percent of weight lost on GLP-1s can come from lean mass depending on study and population. Resistance training two to three sessions per week and adequate protein intake (typically 1.2–1.6 grams per kilogram of body weight per day) significantly reduce lean-mass loss and shift the composition of weight loss toward fat.

Which GLP-1 produces the most weight loss?

In head-to-head and pivotal trial data, tirzepatide 15 mg weekly (Zepbound) produces the largest average total body weight loss, in the low-20s percent range; semaglutide 2.4 mg weekly (Wegovy) produces averages in the mid-teens percent range with the strongest dedicated cardiovascular outcomes data. Cash-pay patients can access compounded versions through PlexusDx Tirzepatide Injection at $249/mo and Semaglutide Injection at $149/mo.

Can I take a GLP-1 if I don’t have type 2 diabetes?

Yes. Wegovy, Zepbound, and Saxenda are FDA-approved specifically for chronic weight management in adults without diabetes, with eligibility based on BMI and weight-related comorbidities rather than diabetes status. Compounded semaglutide and tirzepatide on cash-pay platforms like PlexusDx are likewise prescribed for weight-management indications, not diabetes.

How does PlexusDx pricing compare to branded GLP-1s?

PlexusDx Weight Management Protocols are cash-pay with no membership and ship to all 50 states. Microdose GLP-1 Protocol is $129/mo flat, Semaglutide Injection is $149/mo, Tirzepatide Injection is $249/mo, and GLP-Squared dual-compound is $249/mo — meaningfully below branded list prices. PlexusDx dispenses compounded semaglutide and tirzepatide rather than branded Wegovy or Zepbound; that is a substantive medication-source difference that’s worth understanding before choosing.

GLP-1 Pros and Cons (2026): Benefits, Risks, Costs & PlexusDx Options | PlexusDx